CN105687788A - Pharmaceutical composition capable of softening blood vessels and application thereof - Google Patents
Pharmaceutical composition capable of softening blood vessels and application thereof Download PDFInfo
- Publication number
- CN105687788A CN105687788A CN201610125271.9A CN201610125271A CN105687788A CN 105687788 A CN105687788 A CN 105687788A CN 201610125271 A CN201610125271 A CN 201610125271A CN 105687788 A CN105687788 A CN 105687788A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- pharmaceutical composition
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 45
- 210000004204 blood vessel Anatomy 0.000 title abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 51
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 27
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 25
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 61
- 239000000284 extract Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 210000000582 semen Anatomy 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 239000000080 wetting agent Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- -1 dry Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000012567 medical material Substances 0.000 claims description 2
- 235000017159 Crataegus pinnatifida Nutrition 0.000 claims 8
- 241000657480 Crataegus pinnatifida Species 0.000 claims 8
- 241000628997 Flos Species 0.000 claims 8
- 241000218628 Ginkgo Species 0.000 claims 8
- 241000283956 Manis Species 0.000 claims 8
- 241000237636 Pheretima Species 0.000 claims 8
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims 8
- 241000522620 Scorpio Species 0.000 claims 8
- 239000009490 scorpio Substances 0.000 claims 8
- 238000002156 mixing Methods 0.000 claims 4
- 238000010438 heat treatment Methods 0.000 claims 3
- 238000001914 filtration Methods 0.000 claims 2
- 230000006837 decompression Effects 0.000 claims 1
- 238000002481 ethanol extraction Methods 0.000 claims 1
- 235000011837 pasties Nutrition 0.000 claims 1
- 238000004064 recycling Methods 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 73
- 239000008280 blood Substances 0.000 abstract description 73
- 230000000694 effects Effects 0.000 abstract description 30
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 28
- 244000197580 Poria cocos Species 0.000 abstract description 22
- 235000008599 Poria cocos Nutrition 0.000 abstract description 22
- 230000017531 blood circulation Effects 0.000 abstract description 21
- 244000020518 Carthamus tinctorius Species 0.000 abstract description 20
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract description 20
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract description 20
- 241000208688 Eucommia Species 0.000 abstract description 20
- 241000092665 Atractylodes macrocephala Species 0.000 abstract description 19
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract description 19
- 241000239226 Scorpiones Species 0.000 abstract description 19
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract description 18
- 241001521901 Tribulus lanuginosus Species 0.000 abstract description 18
- 244000061520 Angelica archangelica Species 0.000 abstract description 17
- 235000007516 Chrysanthemum Nutrition 0.000 abstract description 17
- 241000196324 Embryophyta Species 0.000 abstract description 17
- 241000361919 Metaphire sieboldi Species 0.000 abstract description 17
- 240000000249 Morus alba Species 0.000 abstract description 17
- 235000008708 Morus alba Nutrition 0.000 abstract description 17
- 241000283966 Pholidota <mammal> Species 0.000 abstract description 17
- 235000001855 Portulaca oleracea Nutrition 0.000 abstract description 17
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract description 16
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract description 16
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract description 16
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract description 16
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract description 16
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract description 16
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract description 16
- 240000000171 Crataegus monogyna Species 0.000 abstract description 16
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract description 16
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract description 16
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract description 16
- 241000305491 Gastrodia elata Species 0.000 abstract description 16
- 244000194101 Ginkgo biloba Species 0.000 abstract description 16
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract description 16
- 241000157352 Uncaria Species 0.000 abstract description 16
- 240000000031 Achyranthes bidentata Species 0.000 abstract description 15
- 241000675108 Citrus tangerina Species 0.000 abstract description 15
- 244000046146 Pueraria lobata Species 0.000 abstract description 15
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 15
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract description 13
- 240000002853 Nelumbo nucifera Species 0.000 abstract description 10
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract description 10
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract description 10
- 244000292697 Polygonum aviculare Species 0.000 abstract description 10
- 235000006386 Polygonum aviculare Nutrition 0.000 abstract description 10
- 238000002360 preparation method Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 241000287828 Gallus gallus Species 0.000 abstract description 2
- 210000001835 viscera Anatomy 0.000 abstract description 2
- 244000234609 Portulaca oleracea Species 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 36
- 210000004185 liver Anatomy 0.000 description 25
- 210000000952 spleen Anatomy 0.000 description 21
- 244000132619 red sage Species 0.000 description 19
- 230000001737 promoting effect Effects 0.000 description 18
- 206010020772 Hypertension Diseases 0.000 description 17
- 241000219304 Portulacaceae Species 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 206010012735 Diarrhoea Diseases 0.000 description 14
- 241000913745 Spatholobus Species 0.000 description 14
- 235000009508 confectionery Nutrition 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 206010062717 Increased upper airway secretion Diseases 0.000 description 13
- 230000036772 blood pressure Effects 0.000 description 13
- 208000026435 phlegm Diseases 0.000 description 13
- 230000008961 swelling Effects 0.000 description 13
- 210000001015 abdomen Anatomy 0.000 description 12
- 210000002216 heart Anatomy 0.000 description 12
- 235000019640 taste Nutrition 0.000 description 12
- 201000000736 Amenorrhea Diseases 0.000 description 11
- 206010001928 Amenorrhoea Diseases 0.000 description 11
- 208000006820 Arthralgia Diseases 0.000 description 11
- 231100000540 amenorrhea Toxicity 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 11
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 239000002398 materia medica Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 208000004880 Polyuria Diseases 0.000 description 10
- 230000035619 diuresis Effects 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 9
- 206010019233 Headaches Diseases 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 230000003276 anti-hypertensive effect Effects 0.000 description 9
- 208000002173 dizziness Diseases 0.000 description 9
- 231100000869 headache Toxicity 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 208000006673 asthma Diseases 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 206010003210 Arteriosclerosis Diseases 0.000 description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 description 7
- 208000004998 Abdominal Pain Diseases 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 208000005171 Dysmenorrhea Diseases 0.000 description 6
- 206010013935 Dysmenorrhoea Diseases 0.000 description 6
- 206010023126 Jaundice Diseases 0.000 description 6
- 208000037093 Menstruation Disturbances Diseases 0.000 description 6
- 206010027339 Menstruation irregular Diseases 0.000 description 6
- 240000001341 Reynoutria japonica Species 0.000 description 6
- 235000018167 Reynoutria japonica Nutrition 0.000 description 6
- 208000025747 Rheumatic disease Diseases 0.000 description 6
- 241000133134 Saussurea Species 0.000 description 6
- 208000005392 Spasm Diseases 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 230000000552 rheumatic effect Effects 0.000 description 6
- 230000001256 tonic effect Effects 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000001914 calming effect Effects 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 210000000232 gallbladder Anatomy 0.000 description 5
- 208000034783 hypoesthesia Diseases 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 240000005250 Chrysanthemum indicum Species 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000004044 Hypesthesia Diseases 0.000 description 4
- 208000007101 Muscle Cramp Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 238000002386 leaching Methods 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000008713 qiang-huo Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 208000034656 Contusions Diseases 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000008678 sanqi Substances 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000010282 Emodin Substances 0.000 description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 244000237330 gutta percha tree Species 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 241000427159 Achyranthes Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 102100030797 Conserved oligomeric Golgi complex subunit 2 Human genes 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000920113 Homo sapiens Conserved oligomeric Golgi complex subunit 2 Proteins 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000015337 arteriosclerotic cardiovascular disease Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 description 1
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000003840 blood vessel health Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000010227 chenpi Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000010515 dystocia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 208000011318 facial edema Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000002795 scorpion venom Substances 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 208000026843 stiff neck Diseases 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000007371 visceral function Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003911 water pollution Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000010365 xinkeshu Substances 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Insects & Arthropods (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种软化血管的药物组合物,所述药物组合物的原料药由山植叶、丹参、全蝎、穿山甲、牛膝、羌活、白术、白蒺藜、三七、茵陈、桑白皮、鸡血藤、钩藤、红花、香菊、茯苓、雪莲、杜仲叶、当归、川芎、陈皮、虎杖、地龙、马齿苋、银杏叶、葛根、决明子、山楂、天麻组成。该药物组合物配伍符合中药“君臣佐使”原则,重点突出,全面合理,通过口服药物可调节脏腑功能,降低血脂、软化血管,使血质清稀,增加血液流动活力,软化血管效果明显,而且原材料丰富,制备工艺简单,无毒副作用,价格低,在软化血管、治疗和预防“三高”尤其是高血脂方面有良好的应用前景。A pharmaceutical composition for softening blood vessels. The raw materials of the pharmaceutical composition are composed of mountain plant leaves, salvia miltiorrhiza, scorpion, pangolin, achyranthes bidentata, notopterygium, Atractylodes macrocephala, Tribulus terrestris, Panax notoginseng, capillary, Morus alba, chicken Composition of blood vine, uncaria, safflower, fragrant chrysanthemum, poria cocos, snow lotus, Eucommia leaves, angelica, chuanxiong, tangerine peel, knotweed, earthworm, purslane, ginkgo leaves, kudzu root, cassia seed, hawthorn, gastrodia elata. The compatibility of the pharmaceutical composition is in line with the principle of "junchenzuoshi" of traditional Chinese medicine, with prominent focus, comprehensive and reasonable. Oral medicine can regulate viscera function, reduce blood fat, soften blood vessels, make blood thin, increase blood flow vitality, and soften blood vessels. The effect is obvious, and the raw material Rich, simple preparation process, no toxic and side effects, low price, and good application prospects in softening blood vessels, treating and preventing "three highs", especially hyperlipidemia.
Description
技术领域technical field
本发明属于医药技术领域,涉及一种中药组合物,具体涉及一种软化血管的药物组合物及其应用。The invention belongs to the technical field of medicine and relates to a traditional Chinese medicine composition, in particular to a medicinal composition for softening blood vessels and an application thereof.
背景技术Background technique
由于经济的日益发达,现代人生活水平的不断提升,致使人们过多的热爱享受,不注意自己的生活方式、行为习惯、饮食嗜好,从而引起的疾病。快节奏的社会生活,激烈竞争的工作压力,对现代人的身心健康造成了严重的威胁,加上长期的饮食不合理,即:精粮完全取代粗粮,大量的三高(高热、高蛋白、高脂肪)、三多(防腐剂多、增味剂多、激素多)食物的摄入和食物中残留的农药、化肥在体内的存积,再加上空气、水源污染和运动量偏小,肥胖和糖尿病就成了都市一族的富贵病。关于三高是什么有资料统计,在中国人的十大死亡原因中,与代谢疾病相关的死亡率就高达35.7%,与“三高”相关的死亡人数也占总死亡人数的27%。“三高症”是指高血压、高血糖(糖尿病)和高血脂症。高血脂可以引起血管栓塞;高血压可以引起脑出血和脑血管破裂;高血糖可以引起糖尿病。通常伴随着肥胖。它们是现代社会所派生出来的“富贵病”,可能单独存在,也可能相互关联。如:糖尿病人很容易同时患上高血压或高血脂症,而高血脂又是动脉硬化形成和发展的主要因素,动脉硬化患者血管弹性差加剧血压升高,所以后期都形成了“三高症”。世界卫生组织曾经明确提出,防止心血管病的第一道防线就是减少“三高”和控制“三高”。很多糖尿病人都伴有高脂血症,因此人们通常把糖尿病与高脂血症称为姐妹病,并认为高血脂是糖尿病的继发症。据统计大约40%的糖尿病病人有脂代谢紊乱。其特点是甘油三酯增高和高密度脂蛋白降低。Due to the increasingly developed economy and the continuous improvement of modern people's living standards, people love to enjoy too much, and do not pay attention to their own lifestyle, behavior habits, and eating habits, which cause diseases. Fast-paced social life and fierce competition work pressure have caused serious threats to the physical and mental health of modern people, coupled with long-term unreasonable diet, that is: refined grains completely replace coarse grains, a large number of three highs (high heat, high protein, High fat), three excess (more preservatives, more flavor enhancers, more hormones) food intake and the accumulation of pesticides and fertilizers in the food residues in the body, coupled with air and water pollution and less exercise, obesity And diabetes has become a disease of the rich and the rich. About what are the three highs According to statistics, among the top ten causes of death in China, the mortality rate related to metabolic diseases is as high as 35.7%, and the number of deaths related to the "three highs" also accounts for 27% of the total death toll. "Three highs" refers to hypertension, hyperglycemia (diabetes) and hyperlipidemia. Hyperlipidemia can cause vascular embolism; high blood pressure can cause cerebral hemorrhage and cerebrovascular rupture; high blood sugar can cause diabetes. Often accompanied by obesity. They are "diseases of wealth" derived from modern society, and they may exist independently or be related to each other. For example, people with diabetes are likely to suffer from high blood pressure or hyperlipidemia at the same time, and hyperlipidemia is the main factor in the formation and development of arteriosclerosis. The poor elasticity of blood vessels in patients with arteriosclerosis aggravates the increase in blood pressure, so the "three highs" are formed in the later stage ". The World Health Organization once clearly stated that the first line of defense to prevent cardiovascular disease is to reduce and control the "three highs". Many diabetics are accompanied by hyperlipidemia, so people usually call diabetes and hyperlipidemia sister diseases, and think that hyperlipidemia is a secondary disease of diabetes. According to statistics, about 40% of diabetic patients have lipid metabolism disorders. It is characterized by increased triglycerides and decreased high-density lipoproteins.
高血脂症是一种全身性疾病,大量研究资料表明,高血脂症是脑卒中、冠心病、心肌梗死、心脏猝死独立而重要的危险因素。此外,高血脂症也是促进高血压、糖耐量异常、糖尿病的一个重要危险因素。高血脂症还可导致脂肪肝、肝硬化、胆石症、胰腺炎、眼底出血、失明、周围血管疾病、跛行、高尿酸血症。Hyperlipidemia is a systemic disease. A large number of research data show that hyperlipidemia is an independent and important risk factor for stroke, coronary heart disease, myocardial infarction, and sudden cardiac death. In addition, hyperlipidemia is also an important risk factor for hypertension, impaired glucose tolerance, and diabetes. Hyperlipidemia can also lead to fatty liver, liver cirrhosis, cholelithiasis, pancreatitis, fundus hemorrhage, blindness, peripheral vascular disease, claudication, hyperuricemia.
近20年间,人们的食物消费和膳食结构发生了很大改变,由此带来的最显著效应就是高血脂症的发病率不断提升,且逐步出现低龄化。都市白领生活节奏快,工作压力大,饮食不规律,缺乏运动,约40%的人都是高血脂。据统计,我国高血脂患病人数已高达1.6亿,专家估计,全国30岁以上的成年人中间,高血脂症的发病率在10%-20%左右,高血脂症患者人数高达9000万。调查显示,我国每年有250万至300万人死于心血管病,这类疾病已成为危害我国城市和农村人群健康的主要死亡原因。说起心血管疾病,很多人知道与高血压有关,但实际上,潜藏在我们体内,时刻威胁着我们血管健康的还有一个更隐蔽、更厉害的“杀手”,它就是高血脂。专家指出,血脂异常是冠心病、心梗和缺血性脑卒中等心脑血管病的重要危险因素之一。In the past 20 years, people's food consumption and dietary structure have undergone great changes. The most significant effect brought about by this is that the incidence of hyperlipidemia continues to increase, and the age gradually appears younger. Urban white-collar workers have a fast pace of life, high work pressure, irregular diet, and lack of exercise. About 40% of them have hyperlipidemia. According to statistics, the number of patients with hyperlipidemia in my country has reached 160 million. Experts estimate that among adults over the age of 30 in the country, the incidence of hyperlipidemia is about 10%-20%, and the number of patients with hyperlipidemia is as high as 90 million. According to the survey, 2.5 million to 3 million people die of cardiovascular disease in my country every year, and this type of disease has become the main cause of death that endangers the health of urban and rural populations in my country. Speaking of cardiovascular disease, many people know that it is related to high blood pressure, but in fact, there is a hidden and more powerful "killer" hidden in our body that always threatens our blood vessel health, which is hyperlipidemia. Experts pointed out that dyslipidemia is one of the important risk factors for cardiovascular and cerebrovascular diseases such as coronary heart disease, myocardial infarction and ischemic stroke.
近年来青年发生“老年病”逐年增多。动脉硬化性心脑血管病是逐渐发生的,多与不良生活方式,体内毒素的积累环境污染导致血液粘稠凝聚有关,生活、工作紧张、吸烟、酗酒、营养过剩、血粘稠、血液中不正常成份(毒素)等,严重超标,形成动脉硬化,血管炎症和初期的血栓症,中期,血液病变期,青少年甚至婴儿时期、中期、血管病变成血流改变期,中青年即可发生、晚期,脏器损伤期或生命的衰竭期(病发期)血管阻塞严重,超过50%导致心脑血管病,周围血管发生、形成严重的高血压,严重者生命衰竭。In recent years, the occurrence of "senile diseases" among young people has increased year by year. Arteriosclerotic cardiovascular and cerebrovascular diseases occur gradually, and are mostly related to unhealthy lifestyles, accumulation of toxins in the body, and environmental pollution that leads to blood viscosity and coagulation. Stress in life and work, smoking, alcoholism, overnutrition, blood viscosity, and abnormalities in the blood Normal ingredients (toxins), etc., seriously exceed the standard, forming arteriosclerosis, vascular inflammation, and early thrombosis. In the middle stage, the blood lesion stage, adolescents and even infants, in the middle stage, vascular disease becomes the blood flow change stage, which can occur in young and middle-aged people. In the late stage, in the stage of organ damage or the failure stage of life (onset stage), the vascular obstruction is severe, and more than 50% lead to cardiovascular and cerebrovascular diseases, and peripheral blood vessels develop and form severe hypertension, and severe cases are life-threatening.
血管硬化血粘稠是万病之源。由此引起的动脉硬化、高粘滞血症、心脏病、心梗、脑梗、中风、高血压、糖尿病、肿瘤等等呈逐渐上升趋势。高血粘稠引发三高、高血粘引发高血脂、高血粘引发高血压、高血粘加速糖尿病并发症尤为突出。西药在治疗血管硬化血粘稠方面目前治疗效果并不理想,价格高昂,而且通常都伴随有严重的副作用,严重影响病人的身体健康,中药因其副作用小在治疗该类慢性疾病中具有独特优势,但目前缺乏软化血管的有效方剂。Arteriosclerosis and blood viscosity are the source of all diseases. The resulting arteriosclerosis, hyperviscosity, heart disease, myocardial infarction, cerebral infarction, stroke, hypertension, diabetes, tumors, etc. are gradually increasing. High blood viscosity causes three highs, high blood viscosity causes hyperlipidemia, high blood viscosity causes high blood pressure, and high blood viscosity accelerates diabetes complications. Western medicine is currently unsatisfactory in the treatment of arteriosclerosis and blood viscosity, and the price is high, and it is usually accompanied by serious side effects, which seriously affect the patient's health. Traditional Chinese medicine has unique advantages in the treatment of such chronic diseases due to its small side effects , but there is currently no effective prescription for softening blood vessels.
发明内容Contents of the invention
本发明针对现有技术中的不足之处,提供一种软化血管的药物组合物及其应用,该药物组合物工艺简单,成本低,无副作用,在软化血管方面具有显著疗效。The invention aims at the deficiencies in the prior art, and provides a pharmaceutical composition for softening blood vessels and its application. The pharmaceutical composition has simple process, low cost, no side effects, and has remarkable curative effect in softening blood vessels.
本发明的上述目的是通过下述技术方案来实现的:Above-mentioned purpose of the present invention is achieved by following technical scheme:
一种软化血管的药物组合物,所述药物组合物的原料药由山植叶、丹参、全蝎、穿山甲、牛膝、羌活、白术、白蒺藜、三七、茵陈、桑白皮、鸡血藤、钩藤、红花、香菊、茯苓、雪莲、杜仲叶、当归、川芎、陈皮、虎杖、地龙、马齿苋、银杏叶、葛根、决明子、山楂、天麻组成。A pharmaceutical composition for softening blood vessels. The raw materials of the pharmaceutical composition are composed of mountain plant leaves, salvia miltiorrhiza, scorpion, pangolin, achyranthes bidentata, notopterygium, Atractylodes macrocephala, Tribulus terrestris, Panax notoginseng, capillary, Morus alba, chicken Composition of blood vine, uncaria, safflower, fragrant chrysanthemum, poria cocos, snow lotus, Eucommia leaves, angelica, chuanxiong, tangerine peel, knotweed, earthworm, purslane, ginkgo leaves, kudzu root, cassia seed, hawthorn, gastrodia elata.
在一种优选实施方式中,制成所述药物组合物的原料组成及重量份数为:山植叶12-20份,全蝎10-16份,当归3-8份,穿山甲5-12份,牛膝12-17份,丹参7-12份,红花4-9份,白术15-20份,白蒺藜10-15份,茵陈8-12份,桑白皮2-5份,羌活3-7份,鸡血藤11-14份,钩藤9-15份,川芎3-6份,香菊8-13份,雪莲3-5份,杜仲叶1-3份,陈皮5-10份,三七5-10份,虎杖13-16份,地龙3-10份,马齿苋8-13份,银杏叶3-5份,茯苓1-3份,葛根5-10份,决明子3-6份,山楂8-13份,天麻3-5份。In a preferred embodiment, the composition and parts by weight of raw materials for making the pharmaceutical composition are: 12-20 parts of mountain plant leaves, 10-16 parts of scorpion, 3-8 parts of angelica, and 5-12 parts of pangolin , 12-17 parts of Achyranthes bidentata, 7-12 parts of Salvia miltiorrhiza, 4-9 parts of safflower, 15-20 parts of Atractylodes macrocephala, 10-15 parts of Tribulus terrestris, 8-12 parts of capillary, 2-5 parts of mulberry bark, notopterygium 3-7 parts, 11-14 parts of Caulis Spatholobus, 9-15 parts of Uncaria, 3-6 parts of Chuanxiong, 8-13 parts of Fragrant Chrysanthemum, 3-5 parts of Snow Lotus, 1-3 parts of Eucommia Leaf, 5-10 parts of Chenpi 5-10 parts of panax notoginseng, 13-16 parts of knotweed, 3-10 parts of earthworm, 8-13 parts of purslane, 3-5 parts of ginkgo biloba, 1-3 parts of poria cocos, 5-10 parts of kudzu root, cassia seed 3-6 parts, 8-13 parts of Hawthorn, 3-5 parts of Gastrodia elata.
在一种优选实施方式中,制成所述药物组合物的原料组成及重量份数为:山植叶12份,全蝎16份,当归3份,穿山甲12份,牛膝12份,丹参10份,红花9份,白术15份,白蒺藜15份,茵陈8份,桑白皮5份,羌活3份,鸡血藤14份,钩藤9份,川芎6份,香菊8份,雪莲5份,杜仲叶1份,陈皮10份,三七5份,虎杖16份,地龙10份,马齿苋8份,银杏叶5份,茯苓1份,葛根10份,决明子6份,山楂8份,天麻3份。In a preferred embodiment, the composition and parts by weight of raw materials for making the pharmaceutical composition are: 12 parts of mountain plant leaves, 16 parts of scorpion, 3 parts of angelica, 12 parts of pangolin, 12 parts of Achyranthes bidentata, 10 parts of salvia miltiorrhiza 9 parts of safflower, 15 parts of Atractylodes macrocephala, 15 parts of Tribulus terrestris, 8 parts of capillary, 5 parts of Morus alba, 3 parts of Notopterygium, 14 parts of Caulis Spatholobus, 9 parts of Uncaria, 6 parts of Chuanxiong, 8 parts of Xiangju , 5 parts of snow lotus, 1 part of eucommia leaf, 10 parts of tangerine peel, 5 parts of notoginseng, 16 parts of knotweed, 10 parts of earthworm, 8 parts of purslane, 5 parts of ginkgo leaf, 1 part of poria cocos, 10 parts of kudzu root, 6 parts of cassia seed , 8 parts of Hawthorn, 3 parts of Gastrodia elata.
在一种优选实施方式中,制成所述药物组合物的原料组成及重量份数为:山植叶20份,全蝎10份,当归8份,穿山甲5份,牛膝17份,丹参12份,红花4份,白术20份,白蒺藜10份,茵陈12份,桑白皮2份,羌活7份,鸡血藤11份,钩藤15份,川芎3份,香菊13份,雪莲3份,杜仲叶3份,陈皮5份,三七10份,虎杖13份,地龙3份,马齿苋13份,银杏叶3份,茯苓3份,葛根5份,决明子4份,山楂10份,天麻4份。In a preferred embodiment, the composition and parts by weight of raw materials for making the pharmaceutical composition are: 20 parts of mountain plant leaves, 10 parts of scorpion, 8 parts of angelica, 5 parts of pangolin, 17 parts of Achyranthes bidentata, 12 parts of salvia miltiorrhiza 4 parts of safflower, 20 parts of Atractylodes macrocephala, 10 parts of Tribulus terrestris, 12 parts of capillary, 2 parts of Morus alba, 7 parts of notopterygium, 11 parts of Caulis Spatholobus, 15 parts of Uncaria, 3 parts of Chuanxiong, 13 parts of fragrant chrysanthemum , 3 parts of snow lotus, 3 parts of Eucommia leaves, 5 parts of tangerine peel, 10 parts of Panax notoginseng, 13 parts of knotweed, 3 parts of earthworm, 13 parts of purslane, 3 parts of ginkgo biloba, 3 parts of poria cocos, 5 parts of kudzu root, 4 parts of cassia seed , Hawthorn 10 parts, Gastrodia elata 4 parts.
在一种优选实施方式中,制成所述药物组合物的原料组成及重量份数为:山植叶13份,全蝎11份,当归4份,穿山甲6份,牛膝13份,丹参7份,红花5份,白术18份,白蒺藜11份,茵陈9份,桑白皮4份,羌活6份,鸡血藤12份,钩藤13份,川芎4份,香菊9份,雪莲4份,杜仲叶2份,陈皮6份,三七6份,虎杖14份,地龙5份,马齿苋10份,银杏叶4份,茯苓2份,葛根6份,决明子5份,山楂12份,天麻3份。In a preferred embodiment, the composition and parts by weight of raw materials for making the pharmaceutical composition are: 13 parts of mountain plant leaves, 11 parts of scorpion, 4 parts of angelica, 6 parts of pangolin, 13 parts of Achyranthes bidentata, 7 parts of salvia miltiorrhiza 5 parts of safflower, 18 parts of Atractylodes macrocephala, 11 parts of Tribulus terrestris, 9 parts of capillary, 4 parts of Morus alba, 6 parts of notopterygium, 12 parts of Caulis Spatholobus, 13 parts of Uncaria, 4 parts of Chuanxiong, 9 parts of fragrant chrysanthemum , 4 parts of snow lotus, 2 parts of Eucommia leaves, 6 parts of tangerine peel, 6 parts of Panax notoginseng, 14 parts of knotweed, 5 parts of earthworm, 10 parts of purslane, 4 parts of ginkgo biloba, 2 parts of poria cocos, 6 parts of kudzu root, 5 parts of cassia seed , 12 parts of Hawthorn, 3 parts of Gastrodia elata.
在一种优选实施方式中,制成所述药物组合物的原料组成及重量份数为:山植叶17份,全蝎15份,当归7份,穿山甲11份,牛膝16份,丹参8份,红花8份,白术16份,白蒺藜14份,茵陈11份,桑白皮3份,羌活5份,鸡血藤13份,钩藤14份,川芎5份,香菊12份,雪莲3份,杜仲叶1份,陈皮10份,三七9份,虎杖13份,地龙7份,马齿苋11份,银杏叶3份,茯苓1份,葛根10份,决明子4份,山楂11份,天麻4份。In a preferred embodiment, the composition and parts by weight of raw materials for making the pharmaceutical composition are: 17 parts of mountain plant leaves, 15 parts of scorpion, 7 parts of angelica, 11 parts of pangolin, 16 parts of Achyranthes bidentata, 8 parts of salvia miltiorrhiza 8 parts of safflower, 16 parts of Atractylodes macrocephala, 14 parts of Tribulus terrestris, 11 parts of capillary, 3 parts of Morus alba, 5 parts of notopterygium, 13 parts of Caulis Spatholobus, 14 parts of Uncaria, 5 parts of Chuanxiong, 12 parts of fragrant chrysanthemum , 3 parts of snow lotus, 1 part of eucommia leaf, 10 parts of tangerine peel, 9 parts of notoginseng, 13 parts of knotweed, 7 parts of earthworm, 11 parts of purslane, 3 parts of ginkgo leaf, 1 part of poria cocos, 10 parts of kudzu root, 4 parts of cassia seed , Hawthorn 11 parts, Gastrodia elata 4 parts.
在一种优选实施方式中,制成所述药物组合物的原料组成及重量份数为:山植叶15份,全蝎12份,当归5份,穿山甲9份,牛膝15份,丹参9份,红花7份,白术19份,白蒺藜13份,茵陈10份,桑白皮4份,羌活4份,鸡血藤11份,钩藤11份,川芎5份,香菊10份,雪莲5份,杜仲叶3份,陈皮8份,三七8份,虎杖14份,地龙9份,马齿苋12份,银杏叶5份,茯苓3份,葛根8份,决明子6份,山楂9份,天麻5份。In a preferred embodiment, the composition and parts by weight of raw materials for making the pharmaceutical composition are: 15 parts of mountain plant leaves, 12 parts of scorpion, 5 parts of angelica, 9 parts of pangolin, 15 parts of Achyranthes bidentata, 9 parts of salvia miltiorrhiza 7 parts of safflower, 19 parts of Atractylodes macrocephala, 13 parts of Tribulus terrestris, 10 parts of capillary, 4 parts of Morus alba, 4 parts of notopterygium, 11 parts of Caulis Spatholobus, 11 parts of Uncaria, 5 parts of Chuanxiong, and 10 parts of fragrant chrysanthemum , 5 parts of snow lotus, 3 parts of Eucommia leaves, 8 parts of tangerine peel, 8 parts of notoginseng, 14 parts of knotweed, 9 parts of earthworm, 12 parts of purslane, 5 parts of ginkgo leaf, 3 parts of poria cocos, 8 parts of kudzu root, 6 parts of cassia seed , Hawthorn 9 parts, Gastrodia elata 5 parts.
在一种优选实施方式中,制成所述药物组合物的原料组成及重量份数为:山植叶19份,全蝎14份,当归6份,穿山甲7份,牛膝14份,丹参9份,红花6份,白术17份,白蒺藜13份,茵陈10份,桑白皮4份,羌活4份,鸡血藤11份,钩藤11份,川芎5份,香菊10份,雪莲5份,杜仲叶3份,陈皮8份,三七8份,虎杖14份,地龙4份,马齿苋9份,银杏叶5份,茯苓3份,葛根8份,决明子3份,山楂8份,天麻5份。In a preferred embodiment, the composition and parts by weight of raw materials for making the pharmaceutical composition are: 19 parts of mountain plant leaves, 14 parts of scorpion, 6 parts of angelica, 7 parts of pangolin, 14 parts of Achyranthes bidentata, 9 parts of salvia miltiorrhiza 6 parts of safflower, 17 parts of Atractylodes macrocephala, 13 parts of Tribulus terrestris, 10 parts of capillary, 4 parts of Morus alba, 4 parts of notopterygium, 11 parts of Caulis Spatholobus, 11 parts of Uncaria, 5 parts of Chuanxiong, and 10 parts of fragrant chrysanthemum , 5 parts of snow lotus, 3 parts of Eucommia leaves, 8 parts of tangerine peel, 8 parts of Panax notoginseng, 14 parts of knotweed, 4 parts of earthworm, 9 parts of purslane, 5 parts of ginkgo leaf, 3 parts of poria cocos, 8 parts of kudzu root, 3 parts of cassia seed , 8 parts of Hawthorn, 5 parts of Gastrodia elata.
在一种优选实施方式中,所述中药组合物按照下列方法进行制备:In a preferred embodiment, the traditional Chinese medicine composition is prepared according to the following method:
(1)取权利要求2-8任一所述药物组合物中重量组分的各药材,加入5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用;(1) Get each medical material of the weight component in the arbitrary described pharmaceutical composition of claim 2-8, add 5-10 times the amount of ethanol and soak in 1-2 hour, heat extraction 2 times, each 1-2 hour , remove the supernatant, combine the extracts, filter through 100-120 mesh, and then ultra-filter through an ultra-filtration column with a cut-off molecular weight of 5000-10000. Concentrate to a paste, let it stand for later use;
(2)将乙醇提取过的药渣放入10倍量水中,然后放入提取罐加热煮沸1小时,过滤,滤液备用;滤渣加水,第二次加热,煮沸45分钟,过滤,滤液备用;(2) Put the dregs extracted by ethanol into 10 times the amount of water, then put it into an extraction tank and heat and boil for 1 hour, filter, and the filtrate is standby; add water to the filter residue, heat for the second time, boil for 45 minutes, filter, and the filtrate is standby;
(3)将步骤(2)中2次滤液合在一起,用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状;(3) Combine the two filtrates in step (2), filter with gauze, add 50-60% ethanol to the residue, continue leaching for 2 hours at 60°C-70°C, stir once every 10min, filter with gauze, and combine leaching liquid, concentrated into a paste;
(4)将步骤(1)浓缩得到的膏状物与步骤(3)得到的糊状物减压回收乙醇并浓缩至药液浓度为0.6-0.7g生药/mL,抽滤后,滤液的相对密度约为20℃时1.0-1.1;在3000r/min的转速下离心;在60℃-80℃喷雾干燥,得干浸膏;(4) The paste obtained by concentrating step (1) and the paste obtained by step (3) are recovered under reduced pressure to ethanol and concentrated to a concentration of 0.6-0.7g crude drug/mL. After suction filtration, the relative The density is about 1.0-1.1 at 20°C; centrifuge at a speed of 3000r/min; spray dry at 60°C-80°C to obtain a dry extract;
(5)将步骤(4)制得的干浸膏粉碎,加入适量蔗糖、糊精混合,以乙醇为润湿剂,制粒,干燥,整粒,可制得颗粒剂;或者将步骤(4)制得的干浸膏干燥,粉碎,制成散剂;或者将步骤(4)制得的干浸膏粉碎,加入适量微粉硅胶、α-半乳糖混合,以乙醇为润湿剂,制粒,干燥,整粒,装胶囊,制得胶囊剂;或者将步骤(4)制得的干浸膏粉碎,加入适量蔗糖、糊精混合,以乙醇为润湿剂,制粒,干燥,整粒,压片,制得片剂;或者向上述步骤(4)得到的离心后的浓缩液中加入适量蔗糖、香精混合,灭菌,灌装,制得药液剂。(5) Grinding the dry extract prepared in step (4), adding an appropriate amount of sucrose and dextrin to mix, using ethanol as a wetting agent, granulating, drying, and sizing to obtain granules; or the step (4) ) dried and crushed dry extract to make a powder; or crush the dry extract obtained in step (4), add an appropriate amount of micropowder silica gel and α-galactose to mix, use ethanol as a wetting agent, and granulate, Drying, granulation, packing into capsules to obtain capsules; or crushing the dry extract prepared in step (4), adding appropriate amount of sucrose and dextrin to mix, using ethanol as a wetting agent, granulating, drying, and granulation, Tablets are prepared; or an appropriate amount of sucrose and essence are added to the centrifuged concentrate obtained in the above step (4), mixed, sterilized, and filled to obtain a liquid medicine.
本发明还涉及一种所述药物组合物在软化血管药物中的应用。The present invention also relates to an application of the pharmaceutical composition in medicine for softening blood vessels.
本发明所提供的软化血管的药物组合物,其以常见的中草药为原料,充分发挥各组分的药性:The pharmaceutical composition for softening blood vessels provided by the present invention uses common Chinese herbal medicines as raw materials to fully exert the medicinal properties of each component:
山植叶所含山植叶总黄酮有广泛的药理作用,特别有益于心血管系统。实验研究表明,山植叶总黄酮具有降血压、降低外周血管阻力、扩张冠状动脉、增加冠脉流量、降低心肌耗氧量、强心、增加心输出量、抗心肌缺血,抗血小板聚集、改善血液流变性、消除氧自由基、降优和宪、增强耐缺氧能力和利尿等药理作用。临床用于防治冠心病心绞痛、高血压、心律失常及高脂血症、动脉粥样硬化等都是安全、有效的,值得推广应用。山植叶在我国各地特别是西部地区资源非常丰富,有很高的开发价值。The total flavonoids contained in the leaves of the mountain plants have a wide range of pharmacological effects, especially beneficial to the cardiovascular system. Experimental studies have shown that the total flavonoids of mountain plant leaves have the functions of lowering blood pressure, reducing peripheral vascular resistance, expanding coronary arteries, increasing coronary flow, reducing myocardial oxygen consumption, strengthening the heart, increasing cardiac output, anti-myocardial ischemia, anti-platelet aggregation, Improving blood rheology, eliminating oxygen free radicals, detoxifying and reducing blood pressure, enhancing hypoxia tolerance and diuretic and other pharmacological effects. It is safe and effective to prevent and treat angina pectoris of coronary heart disease, hypertension, arrhythmia, hyperlipidemia, atherosclerosis, etc., and is worthy of popularization and application. Shanzhiye is very rich in resources in various parts of our country, especially in the western region, and has high development value.
丹参,苦,微寒。归心、肝经。祛瘀止痛,活血通经,清心除烦。用于月经不调,经闭痛经,症瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠。用于胸肋胁痛,风湿痹痛,症瘕结块,疮疡肿痛,跌仆伤痛,月经不调,经闭痛经,产后瘀痛等。治疗胸肋疼痛、症瘕结块,以及月经不调、经闭经痛具有良效。《纲目》载:丹参,按《妇人明理论》云,四物汤治妇人病,不问产前产后,经水多少,皆可通用,惟一味丹参散,主治与之相同。盖丹参能破宿血,补新血,安生胎,落死胎,止崩中滞下,调经脉。丹参主要成分丹参酮有扩张血管、改善循环、解除血管内凝血等作用,具有活血化痕之功效,并能促进肝脏血液循环,利于肝细胞再生。Danshen, bitter, slightly cold. GUIXIN, Liver Channel. Dispelling blood stasis and relieving pain, promoting blood circulation to stimulate menstrual flow, clearing away heart-fire and relieving restlessness. For irregular menstruation, amenorrhea dysmenorrhea, accumulation of lumps in the abdomen, tingling pain in the chest and abdomen, heat arthralgia pain, sore swelling and pain, vexation and insomnia. It is used for sternocostal and hypochondriac pain, rheumatic arthralgia, lumps in the abdomen, swelling and pain of sores, pain from falls, irregular menstruation, amenorrhea dysmenorrhea, postpartum stasis and pain, etc. It is effective in treating sternocostal pain, lumps in the abdomen, irregular menstruation and amenorrhea. "Compendium" contains: Danshen, according to "Furen Ming Theory", Siwu Decoction can be used to treat women's diseases, regardless of prenatal and postpartum, and the amount of menstrual fluid, but Danshen powder is the same, and the indications are the same. Salvia miltiorrhiza can break old blood, replenish new blood, give birth to a fetus, stop stillbirth, stop stagnation in metrorrhagia, and regulate meridians. Tanshinone, the main component of Danshen, has the effects of dilating blood vessels, improving circulation, and relieving intravascular coagulation. It has the effect of promoting blood circulation and promoting blood circulation in the liver, which is beneficial to liver cell regeneration.
全蝎,食用、药用历史悠久。钳蝎的主要药用成分为蝎毒素,据《本草纲目》和《中国药典》载,全蝎具有“熄风镇痉、消炎攻毒、通络止痛”功能;主治“小儿惊风、抽搐痉挛、皮肤病、心脑血管病、炎症、乙肝、肿瘤”等病。全蝎也是一种高档美味佳肴,营养丰富,食之有防病治病、增强免疫力和抗衰老等功能。Scorpion has a long history of edible and medicinal use. The main medicinal ingredient of the scorpion is scorpion toxin. According to "Compendium of Materia Medica" and "Chinese Pharmacopoeia", the scorpion has the functions of "expelling wind and spasm, reducing inflammation and attacking poison, dredging collaterals and relieving pain"; , skin diseases, cardiovascular and cerebrovascular diseases, inflammation, hepatitis B, tumors and other diseases. Scorpion is also a high-end delicacy, rich in nutrition, and has the functions of preventing and curing diseases, enhancing immunity and anti-aging.
穿山甲,入药部分,穿山甲的鳞甲,功效与作用:活血散结;通经下乳;消痈溃坚。主血瘀经闭;症瘕;风湿痹痛;乳汁不下;痈肿;瘰疬。用于经闭癓瘕,乳汁不通,痈肿疮毒,关节痹痛,麻木拘挛。Pangolin, the part used as medicine, the scales of pangolin, efficacy and action: promoting blood circulation and dispelling stagnation; promoting menstrual flow and releasing breast milk; eliminating carbuncle and ulcer. Main blood stasis amenorrhea; Lump in the abdomen; Rheumatic arthralgia; Milk retention; Carbuncle; Scrofula. For amenorrhea lump in the abdomen, milk barrier, carbuncle sore, joint arthralgia, numbness and spasm.
牛膝:味苦,酸;性平,归肝;肾经,具有补肝肾;强筋骨;活血通经;引火(血)下行;利尿通淋的功效,主治腰膝酸痛;下肢痿软;血滞经闭;痛经;产后血瘀腹痛;症瘕;胞衣不下;热淋;血淋;跌打损伤;痈肿恶疮;咽喉肿痛等证。Radix Achyranthes Radix: bitter in the mouth, sour; Property flat, return liver; Kidney meridian, has liver and kidney invigorating; Strengthening muscles and bones; Promoting blood circulation to stimulate menstrual flow; Causing fire (blood) descending; The effect of inducing diuresis to treat stranguria, mainly cures soreness of the waist and knees; Atrophy of the lower limbs; Amenorrhea due to stagnation of blood; dysmenorrhea; postpartum blood stasis and abdominal pain; lump in the abdomen; retained clothes; hot stranguria; bloody stranguria; bruises;
羌活,味辛;苦;性温。散表寒;祛风湿;利关节;止痛。主外感风寒;头痛无汗;风水浮肿;疮疡肿毒。用于阳痿遗精,遗尿尿频,腰膝冷痛,肾虚作喘,五更泄泻;外用治白癜风,斑秃。解表散寒,祛风胜湿,止痛。Notopterygium, pungent in taste; bitter; warm in nature. Expelling exterior cold; expelling rheumatism; sharpening joints; relieving pain. Main exogenous cold; headache without sweat; Feng Shui edema; sore swelling. For impotence and nocturnal emission, enuresis and frequent urination, cold pain in the waist and knees, asthma due to kidney deficiency, diarrhea at dawn; external use for treating vitiligo and alopecia areata. Relieve the exterior and dispel cold, expelling wind and dampness, relieving pain.
白术味苦、甘,温。归脾、胃经。主治健脾益气,燥湿利水,止汗,安胎。用于脾虚食少,腹胀泄泻,痰饮眩悸,水肿,自汗,胎动不安。白术对瘤细胞有细胞毒作用,能降低瘤细胞的增殖率,减低瘤组织的侵袭性,提高机体抗肿瘤反应的能力。白术挥发油对小鼠艾氏腹水癌、淋巴肉瘤腹水型、食管癌(Ecal09)、肉瘤180等有抑制作用。白术内酯B腹腔注射对小鼠肉瘤民。也有显著抑制作用。《药性论》载其:君,味甘,辛,无毒。能主大风痹,多年气痢,心腹胀痛,破消宿食,开胃,去痰涎,除寒热,止下泄。主面光悦,驻颜,去黑。治水肿胀满,吐呕逆,腹内冷痛,吐泻不住,及胃气虚冷痢。Atractylodes macrocephala bitter in the mouth, sweet, warm. Return spleen, stomach warp. Cure mainly invigorating the spleen and replenishing qi, drying dampness and diuresis, antiperspirant, antiabortive. For insufficiency of the spleen, lack of food, abdominal distension and diarrhea, dizziness and palpitation due to phlegm and retention, edema, spontaneous sweating, restless fetal movement. Atractylodes macrocephala has cytotoxic effect on tumor cells, can reduce the proliferation rate of tumor cells, reduce the invasiveness of tumor tissues, and improve the body's anti-tumor response ability. Atractylodes macrocephala volatile oil has inhibitory effect on Ehrlich ascites carcinoma, lymphosarcoma ascites type, esophageal carcinoma (Ecal09), sarcoma 180, etc. in mice. Effect of intraperitoneal injection of atractyloid B on sarcoma in mice. There is also a significant inhibitory effect. "On the Nature of Medicine" contains it: Jun, sweet in the mouth, pungent, nontoxic. Can control strong wind numbness, dysentery due to dysentery for many years, confidant's distending pain, breaks away food, whets the appetite, removes phlegm and salivation, removes cold and heat, and stops diarrhea. The main face is radiant, calms the face, and removes blackness. Control water swelling and fullness, vomiting and nausea, cold pain in the abdomen, vomiting and diarrhea, and cold dysentery due to stomach qi deficiency.
白蒺藜为蒺藜科一年生或多年生草本植物蒺藜TribulusterrestrisL的成熟果实苦、辛,平,入肝经。平肝解郁,祛风明目。用于肝阳眩晕头痛,肝郁胁痛,风热头痛,目赤肿痛,皮肤瘙痒等症。Tribulus terrestris is the ripe fruit of Tribulus terrestris L, an annual or perennial herb of Tribulus terrestris L, which is bitter, pungent, flat, and enters the Liver Channel. Suppressing liver and relieving stagnation, expelling wind and improving eyesight. For liver yang dizziness headache, liver depression hypochondriac pain, wind-heat headache, conjunctival congestion and swelling pain, skin itching embolism.
三七:三七性甘味微苦,性温,归肝、胃经以根、根状茎入药。是名贵中药材,生用可止血化瘀、消肿止痛,具有良好的止血功效、显著的造血功能;能加强和改善冠脉微循环,三七入药历史悠久,作用奇特被历代医家视为药中之宝,故有“金不换”之说法。三七“味微甘而苦,颇似人参之味。”“凡杖扑伤损,瘀血淋漓者,随即嚼烂罨之即止,青肿者即消散。若受杖时,先服一、二钱,则血不冲心,杖后尤宜服之,产后服亦良。大抵此药气温,味甘微苦,及阳明、厥阴血分之药,故能治一切血病”。《本草求真》记载:“三七,世人仅知功能止血止痛。殊不知痛因血瘀而疼作,血因敷散而血止。三七气味苦温,能于血分化其血瘀。”三七能增加冠脉血流量,减慢心率,减少心肌耗氧量,增加心肌耐氧能力,改善微循环,解除平滑肌痉挛的作用。Radix Notoginseng: Radix Notoginseng is sweet in nature, slightly bitter in taste, warm in nature, and returns to the liver and stomach meridians. Its roots and rhizomes are used as medicine. It is a precious Chinese herbal medicine. It can stop bleeding, remove blood stasis, reduce swelling and relieve pain when used raw. It has good hemostatic effect and significant hematopoietic function; it can strengthen and improve coronary microcirculation. Sanqi has a long history of being used as medicine. Therefore, there is a saying that "gold is not exchanged". Notoginseng "slightly sweet and bitter, similar to the taste of ginseng." "Anyone who is injured by a stick and bruised and dripping with blood should stop immediately after chewing, and the bruise will disappear. If you receive a stick, take a dose first. , two coins, the blood does not rush to the heart, it is especially suitable to be taken after the stick, and it is also good to take after giving birth. Generally speaking, this medicine has a warm temperature, sweet and slightly bitter taste, and it is divided into Yangming and Jueyin blood, so it can cure all blood diseases." . "Materia Medica Seeking Truth" records: "Sanqi, the world only knows its function to stop bleeding and relieve pain. They don't know that pain is caused by blood stasis, and blood stops due to application. The smell of Sanqi is bitter and warm, and it can differentiate blood stasis in the blood." Panax notoginseng can increase coronary blood flow, slow down heart rate, reduce myocardial oxygen consumption, increase myocardial oxygen tolerance, improve microcirculation, and relieve smooth muscle spasm.
茵陈:味苦、辛,性微寒。归脾、胃、肝、胆经。功能主治:清湿热,退黄疸。用于黄疸尿少,湿疮瘙痒;传染性黄疸型肝炎。《本经》:主风湿寒热邪气,热结黄疸。《别录》:治通身发黄,小便不利,除头热,去伏瘕。《本草拾遗》:通关节,去滞热,伤寒用之。《医林纂要》:坚肾,燥脾湿,去郁,解热。《本草再新》:泻火,平肝,化痰,止咳发汗,利湿,消肿,疗疮火诸毒。Yinchen: bitter, pungent, slightly cold in nature. Return spleen, stomach, liver, gall bladder channel. Functions and indications: clearing damp-heat, reducing jaundice. For jaundice oliguria, eczema itching; infectious jaundice hepatitis. "The Classic": main rheumatism, cold and heat evil, heat knot jaundice. "Bie Lu": control the yellowing of the whole body, difficulty in urination, remove head heat, and remove phlegm. "Supplements to Materia Medica": clear joints, remove stagnant heat, and use it for typhoid fever. "Yi Lin Zhuan Yao": strengthening the kidney, drying the spleen and dampness, removing stagnation, and relieving fever. "Materia Medica Zaixin": Purging fire, calming the liver, resolving phlegm, relieving cough and sweating, promoting dampness, reducing swelling, and treating sores and fires.
桑白皮为桑科植物桑MorusalbaL.的根皮。主产于安徽、河南、浙江、江苏、湖南等地。功效:泻肺平喘,利水消肿。用于肺热咳喘,面目浮肿,小便不利等症。《药性论》:使,平。能治肺气喘满,水气浮肿,主伤绝,利水道,消水气,虚劳客热头痛,内补不足。《日华子本草》:温,调中,下气。消痰止渴,利大小肠,开胃,下食,杀腹藏虫,止霍乱吐泻。Morus alba L. is the root bark of the Moraceae plant Morusalba L. Mainly produced in Anhui, Henan, Zhejiang, Jiangsu, Hunan and other places. Efficacy: Xiefei relieves asthma, promotes water to reduce swelling. For lung-heat cough and asthma, facial edema, dysuria embolism. "On the Properties of Medicine": make, flat. It can cure the fullness of the lungs and asthma, water vapor edema, main injury, diuresis, eliminate water vapor, exhaustion and heat headache, deficiency of internal tonic. "Rihuazi Materia Medica": Warming, regulating the middle, lowering the breath. Eliminates phlegm and quenches thirst, sharpens the large and small intestines, whets the appetite, eats food, kills abdominal insects, stops cholera vomiting and diarrhea.
鸡血藤,性苦、甘,温。归肝、肾经,补血,活血,通络。用于月经不调,血虚萎黄,麻木瘫痪,风湿痹痛活血舒筋;养血调经,《本草纲目拾遗》载其能医手足麻木;肢体瘫痪;风湿痹痛;妇女有经不调;痛经。外用是活血化淤的妇科良药。Spatholobus Spatholobus, bitter in nature, sweet, warm. Return liver, kidney meridian, enrich blood, invigorate blood circulation, dredging collaterals. For irregular menstruation, blood deficiency and chlorosis, numbness and paralysis, rheumatic arthralgia, promoting blood circulation and relaxing tendons; nourishing blood and regulating menstruation, "Compendium of Materia Medica Supplements" contains that it can treat numbness of hands and feet; limb paralysis; rheumatic arthralgia; women have irregular menstruation; dysmenorrhea . External use is a good gynecological medicine for promoting blood circulation and removing stasis.
钩藤,味甘,性凉。入肝、心经。能清热平肝,熄风定惊。主治小儿惊痫瘈疭,大人血压偏高,头晕、目眩,妇人子痫。其药理作用具有镇静作用和降压作用。Uncaria, sweet in taste, cool in nature. Go into liver, heart channel. Can clear away heat and calm the liver, calm wind and calm convulsions. It is mainly used to treat children with convulsions and epilepsy, adults with high blood pressure, dizziness and dizziness, and women with eclampsia. Its pharmacological effects have sedative and antihypertensive effects.
红花性温,味辛。功能主治应用于活血通径、散瘀止痛。用于经闭、痛经、恶露不行、症瘕痞块、跌打损伤。《本草汇言》:红花,破血、行血、和血、调血之药也。主胎产百病因血为患,或血烦血晕,神昏不语;或恶露抢心,脐腹绞痛;或沥浆难生,;或胞衣不落,子死腹中,是皆临产诸证,非红花不能治。若产后血晕、口噤指搦;或邪入血室,谵语发狂;或血闷内胀,僵仆如死,是皆产后诸证,非红花不能定。凡如经闭不通而寒热交作,或过期腹痛而紫黑淋漓,或跌扑损伤而气血瘀积,或疮疡痛痒而肿溃不安,是皆气血不和之证,非红花不能调,红花活血通经、消肿止痛,有抑制血栓形成、抗炎、止痛作用,具有消除肾上腺素、去甲肾上腺素的收缩血管作用,有“通利经脉”作用。Safflower is warm in nature and pungent in taste. Functions and indications apply to promoting blood circulation, dispelling blood stasis and relieving pain. For amenorrhea, dysmenorrhea, lochia, lumps in the abdomen, bruises. "Materia Medica Huiyan": Safflower, the medicine for breaking blood, promoting blood circulation, harmonizing blood, and regulating blood. The main fetal birth is caused by various diseases and blood, or blood troubles and blood dizziness, dizziness and silence; or lochia grabs the heart, umbilical abdominal colic; card, non-safflower cannot be cured. If postpartum haemorrhage, mouth shut up and finger pricking; or evil enters the blood chamber, delirium and madness; All such as amenorrhea with cold and heat, or expired abdominal pain with purple and black dripping, or injury with qi and blood stasis, or sores with itching and swollen ulcers are all symptoms of disharmony between qi and blood, and non-safflower cannot Tune in, safflower promote blood circulation and stimulate menstruation, reduce swelling and relieve pain, have the effects of inhibiting thrombosis, anti-inflammation, and pain relief, have the effect of constricting blood vessels by eliminating adrenaline and norepinephrine, and have the effect of "tongli meridian".
香菊:高寒香菊即昆仑雪菊具有高效降血脂、软化血管、去除体内垃圾,达到人体的体液平衡,提高心血输出量,增加心肌供氧量,保护缺血心肌的正常生理功能,对冠心病、高血脂、糖尿病有着特殊的疗效。Fragrant Chrysanthemum: Alpine Fragrant Chrysanthemum, or Kunlun Snow Chrysanthemum, can effectively lower blood fat, soften blood vessels, remove garbage in the body, achieve body fluid balance, increase cardiac output, increase myocardial oxygen supply, and protect normal physiological functions of ischemic myocardium. Heart disease, hyperlipidemia, and diabetes have special curative effects.
茯苓味甘、淡、性平,入药具有利水渗湿、益脾和胃、宁心安神之功用。现代医学研究:茯苓能增强机体免疫功能,茯苓多糖有明显的抗肿瘤及保肝脏作用。茯苓性味甘淡平,入心、肺、脾经。具有渗湿利水,健脾和胃,宁心安神的功效。可治小便不利,水肿胀满,痰饮咳逆,呕逆,恶阻,泄泻,遗精,淋浊,惊悸,健忘等症。茯苓之利水,是通过健运脾肺功能而达到的,与其它直接利水的中药不同。用于脾虚泄泻,带下茯苓既能健脾,又能渗湿,对于脾虚运化失常所致泄泻、带下,应用茯苓有标本兼顾之效,常与党参、白术、山药等配伍。有可用为补肺脾,治气虚之辅佐药。Poria cocos is sweet, light, and flat in nature. When used as medicine, it has the functions of diuresis and dampness, spleen and stomach, and calming the mind. Modern medical research: Poria cocos can enhance the immune function of the body, and Poria cocos polysaccharide has obvious anti-tumor and liver-protecting effects. Poria cocos is sweet and flat in nature and flavor, and enters the heart, lung and spleen meridians. It has the effects of eliminating dampness and diuresis, invigorating the spleen and stomach, calming the mind and calming the nerves. It can cure dysuria, edema and fullness, phlegm retention and cough, vomiting, nausea, diarrhea, spermatorrhea, stranguria, palpitations, and amnesia. The diuresis of Poria cocos is achieved by invigorating the functions of the spleen and lungs, which is different from other traditional Chinese medicines that directly diuresis. For spleen deficiency diarrhea, taking Poria cocos can not only strengthen the spleen, but also ooze dampness. For diarrhea and leukorrhea caused by spleen deficiency, Poria cocos has the effect of taking care of both specimens and is often compatible with Codonopsis pilosula, Atractylodes macrocephala, and Chinese yam. It can be used as an adjuvant medicine for invigorating the lung and spleen and treating qi deficiency.
雪莲:雪莲花具有生理活性有效成分。其中伞形花内酯具有明显的抗菌、降压镇静、解痉作用;具有祛风、抗炎、止痛、祛痰和抗肿瘤作用,能抑制癌细胞的增长,临床用以治疗癌症,特别以乳腺癌有一定疗效,对皮肤癌、白血病和何金氏病等亦有一定作用。对痛风急性发作特异功效。Saussurea: Saussurea has physiologically active active ingredients. Among them, umbelliferone has obvious antibacterial, antihypertensive, sedative, and antispasmodic effects; it has wind-dispelling, anti-inflammatory, pain-relieving, expectorant, and anti-tumor effects, and can inhibit the growth of cancer cells. It is clinically used to treat cancer, especially with Breast cancer has a certain effect, and it also has a certain effect on skin cancer, leukemia and He Jin's disease. Specific effect on acute attack of gout.
杜仲叶为杜仲科植物杜仲EucommiaulmoidesOliv.的干燥叶。夏、秋二季枝叶茂盛时采收,晒干或低温烘干。微辛,温。归肝、肾经。功能与主治:补肝肾,强筋骨。用于肝肾不足,头晕目眩,腰膝酸痛,筋骨痿软。对心血管系统的作用,对心脏的作用杜仲叶水煎醇沉液0.2g对豚鼠离体心脏具有明显增加冠脉血流量的作用。家兔静注20g/kg,对静注异丙肾上腺素引起的ST段抬高和T波改变没有对抗作用。降压作用麻醉犬和猫静注杜仲叶水煎剂0.4g/kg后血压迅速下降,维持5分钟后即逐渐回升;静注1g/kg以上剂量时,血压显著下降,可维持较长时间。醇提取液也有降压作用,但降压幅度及维持时间都比水煎剂差。麻醉犬和猫的降压试验均证明,杜仲叶水煎剂和醇提取液在短期内重复静注给药可产生快速耐受现象,连续给药3-4次甚至不能出现降压效应。杜仲叶的水煎剂和65%乙醇提取液6g/kg静注均可引起家兔血压明显下降。杜仲叶的水溶液、醇溶液、醚溶液及经过提纯的各个成分如糖类、生物碱、桃叶珊瑚甙、绿原酸给家兔静注,均有不同程度的降压作用。Eucommia ulmoides leaves are the dried leaves of Eucommia ulmoides Oliv. Harvest in summer and autumn when the branches and leaves are lush, and dry in the sun or at low temperature. Slightly pungent, warm. Return liver, kidney channel. Functions and indications: nourish liver and kidney, strengthen muscles and bones. For insufficiency of liver and kidney, dizziness, soreness of waist and knees, flaccidity of muscles and bones. The effects on the cardiovascular system and the heart: Eucommia leaf decoction and alcohol precipitation solution 0.2g can significantly increase the coronary blood flow in isolated guinea pig hearts. Intravenous injection of 20g/kg in rabbits has no antagonistic effect on ST-segment elevation and T wave changes caused by intravenous isoproterenol. Antihypertensive effect After intravenous injection of Eucommia leaf water decoction 0.4g/kg in anesthetized dogs and cats, blood pressure drops rapidly and gradually rises after maintaining for 5 minutes; when intravenous injection of doses above 1g/kg, blood pressure drops significantly and can be maintained for a long time. Alcohol extract also has antihypertensive effect, but the antihypertensive range and maintenance time are worse than water decoction. The antihypertensive tests of anesthetized dogs and cats have all proved that repeated intravenous administration of Eucommia leaf water decoction and alcohol extract in a short period of time can produce tachyphylaxis, and the antihypertensive effect cannot even appear after continuous administration of 3-4 times. The water decoction of Eucommia leaves and the 6g/kg intravenous injection of 65% ethanol extract can both cause a significant drop in blood pressure in rabbits. The aqueous solution, alcohol solution, ether solution and purified components of Eucommia leaves, such as sugars, alkaloids, aucubin, and chlorogenic acid, are administered intravenously to rabbits, all of which have different degrees of antihypertensive effects.
当归,其味甘而重,故专能补血,其气轻而辛,故又能行血,补中有动,行中有补,诚血中之气药,亦血中之圣药。大约佐之以补则补,故能养营养血,补气生精,安五脏,强形体,益神志,凡有形虚损之病,无所不宜。佐之以攻则通,故能祛痛通便,利筋骨,治拘挛、瘫痪、燥、涩等证。营虚而表不解者,佐以柴、葛、麻、桂等剂,大能散表卫热,而表不敛者,佐以大黄之类,又能固表。惟其气辛而动,故欲其静者当避之,性滑善行,大便不固者当避之。凡阴中火盛者,当归能动血,亦非所宜,阴中阳虚者,当归能养血,乃不可少。Angelica is sweet and heavy in taste, so it can nourish blood, and its qi is light and pungent, so it can also promote blood, tonic has movement, and tonic has tonic. It is the qi medicine in the blood and the holy medicine in the blood. If it is supplemented with supplements, it will be supplemented, so it can nourish and nourish blood, nourish qi and generate essence, calm the five internal organs, strengthen the body, and benefit the mind. It is suitable for all diseases of physical deficiency. It can relieve pain and relieve constipation, benefit muscles and bones, and treat spasms, paralysis, dryness, astringency and other syndromes. For those who are deficient and unable to understand the exterior, add Chai, Ge, Ma, Gui and other agents, which can greatly dissipate the exterior and defend heat, but for those who do not restrain the exterior, add rhubarb and the like, which can also strengthen the exterior. However, its qi is pungent and moves, so those who want it to be quiet should avoid it, those with slippery nature and good behavior, and those who have loose stools should avoid it. For those with excessive fire in yin, angelica can move blood, which is not suitable. For those with deficiency of yang in yin, angelica can nourish blood, which is indispensable.
川芎,辛,温。入肝、胆经。行气开郁,法风燥湿,活血止痛。治风冷头痛旋晕,胁痛腹疼,寒痹筋挛,经闭,难产,产后瘀阻块痛,痈疽疮疡。用于月经不调,经闭痛经,瘕腹痛,胸胁刺痛,跌扑肿痛,头痛,风湿痹痛。《本经》载其:主中风入脑头痛,寒痹,筋挛缓急,金创,妇人血闭无子。《别录》载其:″除脑中冷动,面上游风去来,目泪出,多涕唾,忽忽如醉,诸寒冷气,心腹坚痛,中恶,卒急肿痛,胁风痛,温中内寒。″是行气化瘀的良药。Rhizoma Chuanxiong, pungent, warm. Go into liver, gallbladder meridian. Promoting qi to relieve depression, eliminating wind and dampness, promoting blood circulation and relieving pain. Control wind-cold headache, dizziness, hypochondriac pain, abdominal pain, arthralgia due to cold, cramps, amenorrhea, dystocia, postpartum stasis block pain, carbuncle sore. For irregular menstruation, amenorrhea dysmenorrhea, abdominal pain in the abdomen, tingling pain in the chest and hypochondrium, tumbling and swelling pain, headache, rheumatic arthralgia. "The Classic" contains it: the main apoplexy into the brain headache, cold arthralgia, spasm emergency, metal wounds, women with blood closed and childless. "Bie Lu" contains it: "In addition to the cold movement in the brain, the wind coming and going upstream on the face, tears coming out of the eyes, excessive tears and saliva, sudden drunkenness, all kinds of cold air, hard pain in the heart and abdomen, evil in the heart, sudden swelling and pain, threat of wind Pain, warming the middle and internal cold." It is a good medicine for promoting qi and removing blood stasis.
陈皮性温,味辛、味苦。入脾经、胃经、肺经。理气健脾,调中,燥湿,化痰。主治脾胃气滞之脘腹胀满或疼痛、消化不良。湿浊阻中之胸闷腹胀、纳呆便溏。痰湿壅肺之咳嗽气喘。用于胸脘胀满,食少吐泻,咳嗽痰多。《本草纲目》:其至百并总是取棋理气燥湿之功,同补药则补,同泻药则泻,同升药则升,同降药则降。脾乃元气之母,肺乃摄气之要,故橘皮为二经气分之要,但随所配而补泻升降也。《日用本草》:能散能泻,能温能补,能消膈气,化痰涎,和脾止嗽,通五淋。Tangerine peel is warm in nature, pungent in taste and bitter in taste. Go into spleen channel, stomach channel, lung channel. Regulates qi and invigorates the spleen, regulates the middle, dries dampness, and resolves phlegm. Indications for abdominal fullness or pain due to stagnation of spleen and stomach Qi, and indigestion. Chest tightness, abdominal distension, loss of appetite and loose stool in damp turbidity resistance. Cough and asthma caused by phlegm damp blocking the lung. It is used for fullness in the chest cavity, vomiting and diarrhea due to lack of food, and cough with excessive phlegm. "Compendium of Materia Medica": It's the best and always take the power of chess to regulate qi and dry dampness. If it is used with tonic, it will be tonic, if it is used with laxative, it will relieve, if it is used with ascending medicine, it will be raised, and if it is used with descending medicine, it will be lowered. The spleen is the mother of vital qi, and the lungs are the key to absorbing qi. Therefore, orange peel is the key to the division of qi in the two meridians, but it can be used to nourish, reduce, and ascend. "Daily Materia Medica": It can disperse and relieve diarrhea, warm and nourish, eliminate diaphragmatic qi, reduce phlegm and salivation, harmonize spleen and relieve cough, and relieve five stranguria.
虎杖微苦、微寒。归肝、胆、肺经。具有清热解毒、利胆退黄、祛风利湿、散瘀定痛、止咳化痰的功能。主治关节痹痛、湿热黄疸、经闭、癓瘕、咳嗽痰多、水火烫伤、跌扑损伤、痈肿疮毒。孕妇慎用。Polygonum cuspidatum slightly bitter, slightly cold. Return liver, gallbladder, lung meridian. It has the functions of clearing heat and detoxifying, promoting gallbladder and reducing jaundice, dispelling wind and dampness, dissipating blood stasis and relieving pain, relieving cough and reducing phlegm. Cure mainly joint arthralgia, damp-heat jaundice, amenorrhea, lump in the abdomen, cough with profuse phlegm, water and fire burns, injury from falls, carbuncle and sore. Pregnant women use with caution.
地龙:味咸性寒,归肝、脾、膀胱经,清热熄风、通络、平喘利尿。现代药理研究地龙具有镇痛、抗惊厥、解热、降压、抗血栓、抗肿瘤等作用。Earthworm: salty in taste and cold in nature, returns to the Liver, Spleen, and Bladder Meridians, clears away heat and relieves wind, dredges collaterals, relieves asthma and promotes diuresis. Modern pharmacological research shows that earthworm has analgesic, anticonvulsant, antipyretic, antihypertensive, antithrombotic, and antitumor effects.
马齿苋利水消肿,降低血压。马齿苋含有大量的钾盐,有良好的利水消肿作用;钾离子还可直接作用于血管壁上,使血管壁扩张,阻止动脉管壁增厚,从而起到降低血压的作用。药用功能是清热解毒,凉血止血。因为它含有丰富的去甲肾上腺素,能促进胰岛腺分泌胰岛素,调节人体糖代谢过程、降低血糖浓度、保持血糖恒定,所以对糖尿病有一定的治疗作用。此外,它还含有一种叫做3—W的不饱和脂肪酸,能抑制胆固醇和甘油三酸酯的生成,对心血管有保护作用。《本草纲目》:“散血消肿,利肠滑胎,解毒通淋,治产后虚汗。”Purslane diuresis reduces swelling and lowers blood pressure. Purslane contains a large amount of potassium salt, which has a good diuresis and swelling effect; potassium ions can also directly act on the blood vessel wall to expand the blood vessel wall and prevent the arterial wall from thickening, thereby lowering blood pressure. The medicinal function is to clear away heat and detoxify, cool blood and stop bleeding. Because it is rich in norepinephrine, it can promote the secretion of insulin by the pancreas, regulate the process of glucose metabolism in the human body, reduce blood sugar concentration, and keep blood sugar constant, so it has a certain therapeutic effect on diabetes. In addition, it also contains a kind of unsaturated fatty acid called 3-W, which can inhibit the production of cholesterol and triglyceride, and has a protective effect on cardiovascular. "Compendium of Materia Medica": "Scatter blood and reduce swelling, sharpen intestines and smooth tires, detoxify and relieve stranguria, and treat postpartum sweating."
银杏叶:功能主治:平喘、活血化瘀、止痛,用于肺虚咳喘、冠心病、心绞痛、高血脂。Ginkgo biloba: functions and indications: relieving asthma, promoting blood circulation and removing blood stasis, relieving pain, used for cough and asthma due to lung deficiency, coronary heart disease, angina pectoris, hyperlipidemia.
葛根,味甘、辛,性凉。入脾、胃经。具有升阳解肌,透疹止泻,除烦止温的功效。用于伤寒、温热头痛项强,烦热消渴,泄泻,痢疾,癍疹不透,高血压,心绞痛,耳聋。临床上用来治疗高血压病颈项强痛、冠心病心绞痛,而且还具有降血糖作用。Radix Puerariae, sweet in taste, pungent, cool in nature. Go into spleen, stomach warp. It has the effects of promoting yang and relieving muscles, penetrating rash and stopping diarrhea, eliminating restlessness and stopping temperature. It is used for typhoid fever, warm-heat headache and strong neck, dysphoria and thirst, diarrhea, dysentery, impervious rash, high blood pressure, angina pectoris, and deafness. It is clinically used to treat stiff neck pain in hypertension, angina pectoris in coronary heart disease, and also has hypoglycemic effect.
决明子为豆科植物决明的成熟种子,亦称为草决明。《神农本草经》记载决明子性甘苦微寒,归肝、胆、肾三经,具有清肝明目,润肠通便,降脂瘦身的功能,可用于头痛眩晕,目赤昏花,大便秘结等,近年来临床上又用于高血压病的治疗。决明子含蒽甙类物质,分解后产生大黄素、大黄素甲醚、大黄酸、大黄酚及葡萄糖等。实验证明,决明子具有降血压、降血脂、抗菌等作用,用于治疗高脂血症有一定疗效。除药用成分外,决明子还含有多种维生素和丰富的氨基酸、碳水化合物等。Cassia is the mature seed of the leguminous plant Cassia, also known as Cassia. "Shen Nong's Materia Medica" records that cassia seed is sweet, bitter and slightly cold, and belongs to the three meridians of liver, gallbladder and kidney. etc. In recent years, it has been used clinically for the treatment of hypertension. Semen Cassiae contains anthracene glycosides, which can be decomposed to produce emodin, emodin methyl ether, rhein, chrysophanol and glucose. Experiments have proved that Semen Cassiae has the functions of lowering blood pressure, lowering blood fat, and antibacterial effects, and has certain curative effect in treating hyperlipidemia. In addition to medicinal ingredients, cassia seeds also contain a variety of vitamins and rich amino acids, carbohydrates and so on.
山楂:性,微温。味,甘、酸。入脾、胃、肝经。本品善行气散结,消食化积之效;通行气血,活血祛瘀,治疗高血脂症、高血压均有较好疗效;其能降血脂,抗动脉粥样硬化,又能降低血清胆固醇及甘油三酯;还能扩张冠状动脉,增加冠脉流量,保护心肌缺血缺氧,强心、降血压及抗心律失常;化瘀血而不伤新血,开郁气而不伤正气,其性尤和平也。Hawthorn: sex, slightly warm. Taste, sweet, sour. Go into spleen, stomach, liver channel. This product is good at dispelling stagnation of qi, eliminating indigestion and accumulation; it circulates qi and blood, promotes blood circulation and removes blood stasis, and has good curative effect on treating hyperlipidemia and hypertension; it can lower blood fat, resist atherosclerosis, and lower serum cholesterol and triglycerides; it can also expand coronary arteries, increase coronary flow, protect myocardial ischemia and hypoxia, strengthen the heart, lower blood pressure and resist arrhythmia; remove blood stasis without hurting new blood, open up depression without hurting righteousness, Its nature is especially peaceful.
天麻:性,平。味,甘。主入肝经。本品息风止痉,平抑肝阳,祛风通络。为治眩晕、头痛之要药;又于肢体麻木、手足不遂、风湿痹痛,筋骨拘挛之佳品。Gastrodia elata: sex, flat. taste, sweet. Mainly enters the Liver Channel. This product relieves wind and spasm, calms liver-yang, dispels wind and dredges collaterals. It is an important medicine for treating dizziness and headache; it is also a good product for numbness of limbs, paralysis of hands and feet, rheumatic arthralgia, and spasm of muscles and bones.
中医理论认为,“三高”症病主要是由心、肝、肾功能的阴阳失调,加上感受风、热、毒等外邪侵袭,与人体内的痰、瘀互相交结,以及各种因素互相影响所致。因此,通过平肝潜阳,理气活血,滋阴养肾,清热祛瘀是治疗“三高”症病的有效途径。理想的药物应是在软化血管的同时能够逆转其病理过程,防治并发症的发生,且应无明显的毒副作用。本发明是基于上述理论,集多种中草药研制而成。其本发明可以快速活血化瘀,通经活络,用于高血脂,降血粘、软化血管、调节血脂,对于治疗和预防“三高”具有独特疗效。The theory of traditional Chinese medicine believes that the "three highs" are mainly caused by the imbalance of yin and yang in the functions of the heart, liver, and kidneys, plus the invasion of external evils such as wind, heat, and poison, and the interaction of phlegm and blood stasis in the human body, as well as various factors. caused by mutual influence. Therefore, it is an effective way to treat the "three highs" by calming the liver and suppressing yang, regulating qi and promoting blood circulation, nourishing yin and nourishing kidney, clearing heat and removing blood stasis. An ideal drug should be able to reverse its pathological process while softening blood vessels, prevent and prevent complications, and should have no obvious toxic and side effects. The present invention is based on the above-mentioned theory and is developed by integrating various Chinese herbal medicines. The present invention can quickly promote blood circulation and remove blood stasis, dredge meridians and activate collaterals, be used for hyperlipidemia, reduce blood viscosity, soften blood vessels, and regulate blood lipids, and has unique curative effects for treating and preventing "three highs".
本发明的软化血管的药物组合物配伍符合中药“君臣佐使”原则,重点突出,全面合理,通过口服药物可调节脏腑功能,降低血脂、软化血管,使血质清稀,增加血液流动活力,软化血管效果明显,而且原材料丰富,制备工艺简单,无毒副作用,价格低,在软化血管、治疗和预防“三高”尤其是高血脂方面有良好的应用前景。The compatibility of the pharmaceutical composition for softening blood vessels of the present invention conforms to the principle of "junchenzuoshi" of traditional Chinese medicine, with prominent focus and comprehensive rationality. Oral medicine can regulate visceral functions, reduce blood lipids, soften blood vessels, make blood thinner, increase blood flow vitality, and soften blood vessels The invention has obvious effects, abundant raw materials, simple preparation process, no toxic and side effects, and low price, and has good application prospects in softening blood vessels, treating and preventing "three highs", especially hyperlipidemia.
具体实施方式detailed description
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合实施例对本发明的技术方案进行清楚、完整地描述。显然,所描述的实施例是本发明的一部分,而不是全部的实施例。基于所描述的本发明的实施例,本领域普通技术人员在无需创造性劳动的前提下所获得的所有其他实施例,都属于本发明保护的范围。除非另有说明,本发明中的乙醇量的百分数是体积百分数,v/v表示溶液的体积比。In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions of the present invention will be clearly and completely described below in conjunction with the embodiments. Apparently, the described embodiments are part, but not all, of the present invention. Based on the described embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without creative efforts shall fall within the protection scope of the present invention. Unless otherwise specified, the percentage of ethanol in the present invention is volume percentage, and v/v represents the volume ratio of the solution.
实施例1:Example 1:
本发明的一种软化血管的药物组合物,取下列中药原料药:山植叶12克,全蝎16克,当归3克,穿山甲12克,牛膝12克,丹参10克,红花9克,白术15克,白蒺藜15克,茵陈8克,桑白皮5克,羌活3克,鸡血藤14克,钩藤9克,川芎6克,香菊8克,雪莲5克,杜仲叶1克,陈皮10克,三七5克,虎杖16克,地龙10克,马齿苋8克,银杏叶5克,茯苓1克,葛根10克,决明子6克,山楂8克,天麻3克。A pharmaceutical composition for softening blood vessels of the present invention, the following Chinese medicine raw materials are taken: 12 grams of mountain plant leaves, 16 grams of scorpion, 3 grams of angelica, 12 grams of pangolin, 12 grams of Achyranthes bidentata, 10 grams of salvia miltiorrhiza, 9 grams of safflower , 15 grams of Atractylodes macrocephala, 15 grams of Tribulus terrestris, 8 grams of capillary, 5 grams of Morus alba, 3 grams of Qianghuo, 14 grams of Caulis Spatholobus, 9 grams of Uncaria, 6 grams of Chuanxiong, 8 grams of fragrant chrysanthemum, 5 grams of Saussurea ulmoides, Eucommia 1 gram of leaves, 10 grams of tangerine peel, 5 grams of Panax notoginseng, 16 grams of Polygonum cuspidatum, 10 grams of earthworm, 8 grams of purslane, 5 grams of ginkgo leaf, 1 gram of poria cocos, 10 grams of kudzu root, 6 grams of cassia seed, 8 grams of hawthorn, Gastrodia elata 3 grams.
实施例2:Example 2:
本发明的一种软化血管的药物组合物,取下列中药原料药:山植叶20克,全蝎10克,当归8克,穿山甲5克,牛膝17克,丹参12克,红花4克,白术20克,白蒺藜10克,茵陈12克,桑白皮2克,羌活7克,鸡血藤11克,钩藤15克,川芎3克,香菊13克,雪莲3克,杜仲叶3克,陈皮5克,三七10克,虎杖13克,地龙3克,马齿苋13克,银杏叶3克,茯苓3克,葛根5克,决明子4克,山楂10克,天麻4克。A pharmaceutical composition for softening blood vessels of the present invention, the following traditional Chinese medicine raw materials are taken: 20 grams of mountain plant leaves, 10 grams of scorpion, 8 grams of angelica, 5 grams of pangolin, 17 grams of Achyranthes bidentata, 12 grams of salvia miltiorrhiza, 4 grams of safflower , 20 grams of Atractylodes macrocephala, 10 grams of Tribulus terrestris, 12 grams of capillary, 2 grams of Morus alba, 7 grams of Qianghuo, 11 grams of Caulis Spatholobus, 15 grams of Uncaria, 3 grams of Chuanxiong, 13 grams of fragrant chrysanthemum, 3 grams of Saussurea ulmoides, Eucommia 3 grams of leaves, 5 grams of tangerine peel, 10 grams of Panax notoginseng, 13 grams of Polygonum cuspidatum, 3 grams of earthworm, 13 grams of purslane, 3 grams of ginkgo biloba, 3 grams of Poria cocos, 5 grams of kudzu root, 4 grams of cassia seed, 10 grams of hawthorn, Gastrodia elata 4 grams.
实施例3:Example 3:
本发明的一种软化血管的药物组合物,取下列中药原料药:山植叶13克,全蝎11克,当归4克,穿山甲6克,牛膝13克,丹参7克,红花5克,白术18克,白蒺藜11克,茵陈9克,桑白皮4克,羌活6克,鸡血藤12克,钩藤13克,川芎4克,香菊9克,雪莲4克,杜仲叶2克,陈皮6克,三七6克,虎杖14克,地龙5克,马齿苋10克,银杏叶4克,茯苓2克,葛根6克,决明子5克,山楂12克,天麻3克。A pharmaceutical composition for softening blood vessels of the present invention, the following Chinese medicine raw materials are taken: 13 grams of mountain plant leaves, 11 grams of scorpion, 4 grams of angelica, 6 grams of pangolin, 13 grams of Achyranthes bidentata, 7 grams of salvia miltiorrhiza, 5 grams of safflower , 18 grams of Atractylodes macrocephala, 11 grams of Tribulus terrestris, 9 grams of capillary, 4 grams of Morus alba, 6 grams of notopterygium, 12 grams of Caulis Spatholobus, 13 grams of Uncaria, 4 grams of Chuanxiong, 9 grams of fragrant chrysanthemum, 4 grams of snow lotus, Eucommia 2 grams of leaves, 6 grams of tangerine peel, 6 grams of Panax notoginseng, 14 grams of Polygonum cuspidatum, 5 grams of earthworm, 10 grams of purslane, 4 grams of ginkgo biloba leaves, 2 grams of Poria cocos, 6 grams of kudzu root, 5 grams of cassia seed, 12 grams of hawthorn, Gastrodia elata 3 grams.
实施例4:Example 4:
本发明的一种软化血管的药物组合物,取下列中药原料药:山植叶17克,全蝎15克,当归7克,穿山甲11克,牛膝16克,丹参8克,红花8克,白术16克,白蒺藜14克,茵陈11克,桑白皮3克,羌活5克,鸡血藤13克,钩藤14克,川芎5克,香菊12克,雪莲3克,杜仲叶1克,陈皮10克,三七9克,虎杖13克,地龙7克,马齿苋11克,银杏叶3克,茯苓1克,葛根10克,决明子4克,山楂11克,天麻4克。A pharmaceutical composition for softening blood vessels of the present invention, the following traditional Chinese medicine raw materials are taken: 17 grams of mountain plant leaves, 15 grams of scorpion, 7 grams of angelica, 11 grams of pangolin, 16 grams of Achyranthes bidentata, 8 grams of salvia miltiorrhiza, and 8 grams of safflower , 16 grams of Atractylodes macrocephala, 14 grams of Tribulus terrestris, 11 grams of capillary, 3 grams of Morus alba, 5 grams of notopterygium, 13 grams of Caulis Spatholobus, 14 grams of Uncaria, 5 grams of Chuanxiong, 12 grams of fragrant chrysanthemum, 3 grams of snow lotus, Eucommia 1 gram of leaves, 10 grams of tangerine peel, 9 grams of Panax notoginseng, 13 grams of Polygonum cuspidatum, 7 grams of earthworm, 11 grams of purslane, 3 grams of ginkgo leaf, 1 gram of poria cocos, 10 grams of kudzu root, 4 grams of cassia seed, 11 grams of hawthorn, Gastrodia elata 4 grams.
实施例5:Example 5:
本发明的一种软化血管的药物组合物,取下列中药原料药:山植叶15克,全蝎12克,当归5克,穿山甲9克,牛膝15克,丹参9克,红花7克,白术19克,白蒺藜13克,茵陈10克,桑白皮4克,羌活4克,鸡血藤11克,钩藤11克,川芎5克,香菊10克,雪莲5克,杜仲叶3克,陈皮8克,三七8克,虎杖14克,地龙9克,马齿苋12克,银杏叶5克,茯苓3克,葛根8克,决明子6克,山楂9克,天麻5克。A pharmaceutical composition for softening blood vessels of the present invention, the following Chinese medicine raw materials are taken: 15 grams of mountain plant leaves, 12 grams of scorpion, 5 grams of angelica, 9 grams of pangolin, 15 grams of Achyranthes bidentata, 9 grams of salvia miltiorrhiza, 7 grams of safflower , 19 grams of Atractylodes macrocephala, 13 grams of Tribulus terrestris, 10 grams of capillary, 4 grams of Morus alba, 4 grams of Qianghuo, 11 grams of Caulis Spatholobus, 11 grams of Uncaria, 5 grams of Chuanxiong, 10 grams of fragrant chrysanthemum, 5 grams of Saussurea ulmoides, Eucommia 3 grams of leaves, 8 grams of tangerine peel, 8 grams of Panax notoginseng, 14 grams of Polygonum cuspidatum, 9 grams of earthworm, 12 grams of purslane, 5 grams of ginkgo leaf, 3 grams of poria cocos, 8 grams of kudzu root, 6 grams of cassia seed, 9 grams of hawthorn, Gastrodia elata 5 grams.
实施例6:Embodiment 6:
本发明的一种软化血管的药物组合物,取下列中药原料药:山植叶19克,全蝎14克,当归6克,穿山甲7克,牛膝14克,丹参9克,红花6克,白术17克,白蒺藜13克,茵陈10克,桑白皮4克,羌活4克,鸡血藤11克,钩藤11克,川芎5克,香菊10克,雪莲5克,杜仲叶3克,陈皮8克,三七8克,虎杖14克,地龙4克,马齿苋9克,银杏叶5克,茯苓3克,葛根8克,决明子3克,山楂8克,天麻5克。A pharmaceutical composition for softening blood vessels of the present invention, the following traditional Chinese medicine raw materials are taken: 19 grams of mountain plant leaves, 14 grams of scorpion, 6 grams of angelica, 7 grams of pangolin, 14 grams of Achyranthes bidentata, 9 grams of salvia miltiorrhiza, 6 grams of safflower , 17 grams of Atractylodes macrocephala, 13 grams of Tribulus terrestris, 10 grams of capillary, 4 grams of Morus alba, 4 grams of Qianghuo, 11 grams of Caulis Spatholobus, 11 grams of Uncaria, 5 grams of Chuanxiong, 10 grams of fragrant chrysanthemum, 5 grams of Saussurea ulmoides, Eucommia 3 grams of leaves, 8 grams of tangerine peel, 8 grams of Panax notoginseng, 14 grams of knotweed, 4 grams of earthworm, 9 grams of purslane, 5 grams of ginkgo leaves, 3 grams of poria cocos, 8 grams of kudzu root, 3 grams of cassia seed, 8 grams of hawthorn, Gastrodia elata 5 grams.
其中,实施例1-6的所述中药组合物的制备方法为:Wherein, the preparation method of the described Chinese medicine composition of embodiment 1-6 is:
(1)取实施例1-6任一所述中药组合物中重量组分的各药材,加入5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用;(1) Get each medicinal material of the weight component in the Chinese medicine composition described in any one of embodiments 1-6, add 5-10 times the amount of ethanol and soak for 1-2 hours, heat and extract 2 times, each 1-2 hours , remove the supernatant, combine the extracts, filter through 100-120 mesh, and then ultra-filter through an ultra-filtration column with a cut-off molecular weight of 5000-10000. Concentrate to a paste, let it stand for later use;
(2)将乙醇提取过的药渣放入10倍量水中,然后放入提取罐加热煮沸1小时,过滤,滤液备用;滤渣加水,第二次加热,煮沸45分钟,过滤,滤液备用;(2) Put the dregs extracted by ethanol into 10 times the amount of water, then put it into an extraction tank and heat and boil for 1 hour, filter, and the filtrate is standby; add water to the filter residue, heat for the second time, boil for 45 minutes, filter, and the filtrate is standby;
(3)将步骤(2)中2次滤液合在一起,用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状;(3) Combine the two filtrates in step (2), filter with gauze, add 50-60% ethanol to the residue, continue leaching for 2 hours at 60°C-70°C, stir once every 10min, filter with gauze, and combine leaching liquid, concentrated into a paste;
(4)将步骤(1)浓缩得到的膏状物与步骤(3)得到的糊状物减压回收乙醇并浓缩至药液浓度为0.6-0.7g生药/mL,抽滤后,滤液的相对密度约为20℃时1.0-1.1;在3000r/min的转速下离心;在60℃-80℃喷雾干燥,得干浸膏;(4) The paste obtained by concentrating step (1) and the paste obtained by step (3) are recovered under reduced pressure to ethanol and concentrated to a concentration of 0.6-0.7g crude drug/mL. After suction filtration, the relative The density is about 1.0-1.1 at 20°C; centrifuge at a speed of 3000r/min; spray dry at 60°C-80°C to obtain a dry extract;
(5)将步骤(4)制得的干浸膏粉碎,加入适量蔗糖、糊精混合,以乙醇为润湿剂,制粒,干燥,整粒,可制得颗粒剂;或者将步骤(4)制得的干浸膏干燥,粉碎,制成散剂;或者将步骤(4)制得的干浸膏粉碎,加入适量微粉硅胶、α-半乳糖混合,以乙醇为润湿剂,制粒,干燥,整粒,装胶囊,制得胶囊剂;或者将步骤(4)制得的干浸膏粉碎,加入适量蔗糖、糊精混合,以乙醇为润湿剂,制粒,干燥,整粒,压片,制得片剂;或者向上述步骤(4)得到的离心后的浓缩液中加入适量蔗糖、香精混合,灭菌,灌装,制得药液剂。(5) Grinding the dry extract prepared in step (4), adding an appropriate amount of sucrose and dextrin to mix, using ethanol as a wetting agent, granulating, drying, and sizing to obtain granules; or the step (4) ) dried and crushed dry extract to make a powder; or crush the dry extract obtained in step (4), add an appropriate amount of micropowder silica gel and α-galactose to mix, use ethanol as a wetting agent, and granulate, Drying, granulation, packing into capsules to obtain capsules; or crushing the dry extract prepared in step (4), adding appropriate amount of sucrose and dextrin to mix, using ethanol as a wetting agent, granulating, drying, and granulation, Tablets are prepared; or an appropriate amount of sucrose and essence are added to the centrifuged concentrate obtained in the above step (4), mixed, sterilized, and filled to obtain a liquid medicine.
急性毒性试验Acute Toxicity Test
方法一:method one:
试验材料:昆明种小鼠40只,体重22-25g。药物:本发明实施例3制得的药液剂,含0.0365mg/ml。Test materials: 40 Kunming mice, weighing 22-25g. Medicine: the medicinal liquid prepared in Example 3 of the present invention, containing 0.0365mg/ml.
方法:method:
LD50计算:采用改良寇氏法,将小鼠随机分成4组,每组10只,将本发明实施例3制得的药液剂加蒸馏水溶解,配成最大浓度,按小鼠最大允许容量给药,所给剂量按生药量依次为18,14.4,11.5,9.2,7.4(g.kg-1),在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml,观察动物死亡情况。Calculation of LD50: Using the modified Cole's method, the mice were randomly divided into 4 groups, 10 in each group, and the medicinal solution prepared in Example 3 of the present invention was dissolved in distilled water to make the maximum concentration, and given according to the maximum allowable capacity of the mice. The given dosage is 18, 14.4, 11.5, 9.2, 7.4 (g.kg-1) in sequence according to the crude drug amount, and after the animal is fasted (without water) for 18 hours, it is divided into two doses in one day (half an hour apart). ), 0.5ml each time, and observe the death of the animals.
试验结果:在LD50计算中当用最大允许浓度和最大允许容量给予小鼠时(18g/Kg.d),未见小鼠死亡,即未测出LD50,只可求最大耐受剂量,给药后观察14天,小鼠无一死亡,主要脏器未见异常,亦未见其它明显异常,第14天处死并剖检部分小鼠,肉眼观察主要脏器未见异常。即选用相当于临床剂量的300倍药量,并无不良反应发生,表明急性毒性极小,MTD>18g/Kg.d。Test results: in the LD50 calculation, when the mice were administered with the maximum allowable concentration and the maximum allowable capacity (18g/Kg.d), no death of the mice was seen, that is, the LD50 was not measured, and only the maximum tolerated dose could be obtained. After 14 days of observation, none of the mice died, no abnormalities were found in the main organs, and no other obvious abnormalities were found. On the 14th day, some mice were sacrificed and autopsied, and no abnormalities were found in the main organs. That is, the dosage equivalent to 300 times of the clinical dose was selected, and no adverse reaction occurred, indicating that the acute toxicity was extremely small, and the MTD was greater than 18g/Kg.d.
六个月长期毒性试验:给药期间每周称体重一次,每日称食量,无死亡或濒死动物,结果小鼠毛色光洁,行为活动、腺体分泌、呼吸、粪便性状均正常。病理检查提示,对各种脏器无明显药物所致病理改变。Six-month long-term toxicity test: During the administration period, the body weight was weighed once a week, and the food intake was weighed every day. No dead or dying animals were found. The results showed that the mice had smooth coats, and their behaviors, gland secretions, breathing, and feces were normal. Pathological examination indicated that there were no obvious drug-induced pathological changes in various organs.
临床论证:Clinical justification:
为了验证本发明药物组合物的效果,2012年10月-2014年5月,门诊处随机抽取高血脂患者180例,年龄45~68(55±10.41)岁,男性患者88例,女性患者92例。高血脂病史3~16(8.92±3.21)年,体重、身高、运动、饮食等没有明显差异,P>0.05,其中1期高血压患者90例,2期期高血压患者65例,3期高血压患者25例。随机分为治疗组和对照组各90例。In order to verify the effect of the pharmaceutical composition of the present invention, from October 2012 to May 2014, 180 patients with hyperlipidemia were randomly selected in the outpatient department, aged 45 to 68 (55±10.41) years old, 88 male patients and 92 female patients . The history of hyperlipidemia ranged from 3 to 16 (8.92±3.21) years, and there was no significant difference in weight, height, exercise, diet, etc., P>0.05, including 90 patients with stage 1 hypertension, 65 patients with stage 2 hypertension, and 65 patients with stage 3 hypertension. 25 patients with blood pressure. They were randomly divided into treatment group and control group, 90 cases each.
心电图和实验室检查:ECG and laboratory tests:
入院后均常规检查血压(BP)、心电图(ECG)、糖化血红蛋白(Hbaic%)、甘油三酯(TG)、低密度脂蛋白(LDLC)、高密度脂蛋白fHDL)等。After admission, blood pressure (BP), electrocardiogram (ECG), glycosylated hemoglobin (Hbaic%), triglyceride (TG), low-density lipoprotein (LDLC), high-density lipoprotein (fHDL), etc. were routinely checked.
治疗treat
对照组进行常规治疗,采用心可舒片、降脂灵片等常规药物治疗,积极运动。The control group received routine treatment, such as Xinkeshu Tablets, Jiangzhiling Tablets and other conventional drugs, and active exercise.
治疗组使用实施例3之片剂来进行治疗,每次两片,每日2-3次,10天一个疗程,连续治疗2-4个疗程,不增加其他中医或西医的治疗方法。The treatment group used the tablet of Example 3 for treatment, two tablets each time, 2-3 times a day, 10 days as a course of treatment, 2-4 courses of continuous treatment, without adding other treatment methods of traditional Chinese medicine or western medicine.
疗效判定标准Efficacy criteria
治愈:症状全部消失;主要理化检测指标均为正常。Cure: all the symptoms disappeared; the main physical and chemical indicators were normal.
显效:全部症状消除或主要症状消除;理化检测指标基本正常。Significantly effective: all symptoms or main symptoms are eliminated; physical and chemical detection indicators are basically normal.
有效:主要症状基本消失;主要理化检测指标有所改善。Effective: the main symptoms basically disappeared; the main physical and chemical detection indicators improved.
无效:主要理化检测指标与治疗前无变化。Invalid: The main physical and chemical detection indicators have no change from before treatment.
结果:result:
两组病例治疗后的疗效对照结果如下表:The curative effect comparison results of the two groups of cases after treatment are as follows:
两组患者临床疗效比较(例%)Comparison of clinical curative effect between two groups of patients (case %)
两组患者临床疗效比较:治疗组总有效率为96.7%,对照组为46.7%,两组比较差异有统计学意义(P<0.05)。治疗组优于对照组。可见,本发明优选实施方式制得的药物能够安全有效软化血管,有效率显著高于对照组。Comparison of clinical efficacy between the two groups: the total effective rate was 96.7% in the treatment group and 46.7% in the control group, and the difference between the two groups was statistically significant (P<0.05). The treatment group was better than the control group. It can be seen that the medicine prepared in the preferred embodiment of the present invention can safely and effectively soften blood vessels, and the effective rate is significantly higher than that of the control group.
最后应说明的是:以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。Finally, it should be noted that: the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those of ordinary skill in the art should understand that: it can still be Modifications are made to the technical solutions described in the foregoing embodiments, or equivalent replacements are made to some of the technical features; and these modifications or replacements do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610125271.9A CN105687788A (en) | 2016-03-04 | 2016-03-04 | Pharmaceutical composition capable of softening blood vessels and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610125271.9A CN105687788A (en) | 2016-03-04 | 2016-03-04 | Pharmaceutical composition capable of softening blood vessels and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105687788A true CN105687788A (en) | 2016-06-22 |
Family
ID=56220812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610125271.9A Pending CN105687788A (en) | 2016-03-04 | 2016-03-04 | Pharmaceutical composition capable of softening blood vessels and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105687788A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106038971A (en) * | 2016-07-06 | 2016-10-26 | 侯小芳 | Traditional Chinese medicine for treating hypertension and preparation method of traditional Chinese medicine for treating hypertension |
CN107616261A (en) * | 2017-10-27 | 2018-01-23 | 羊楼洞茶业股份有限公司 | One kind thorn certain kind of berries green brick tea and preparation method thereof |
CN114224979A (en) * | 2021-12-23 | 2022-03-25 | 庞德东 | Medicine for softening blood vessel and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104304602A (en) * | 2014-11-24 | 2015-01-28 | 青岛恒波仪器有限公司 | Pagoda tree fruit tea capable of softening blood vessels and preparation method thereof |
CN104857121A (en) * | 2015-05-05 | 2015-08-26 | 青岛市市立医院 | Drug combination for curing hyperlipidemia and application thereof |
-
2016
- 2016-03-04 CN CN201610125271.9A patent/CN105687788A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104304602A (en) * | 2014-11-24 | 2015-01-28 | 青岛恒波仪器有限公司 | Pagoda tree fruit tea capable of softening blood vessels and preparation method thereof |
CN104857121A (en) * | 2015-05-05 | 2015-08-26 | 青岛市市立医院 | Drug combination for curing hyperlipidemia and application thereof |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106038971A (en) * | 2016-07-06 | 2016-10-26 | 侯小芳 | Traditional Chinese medicine for treating hypertension and preparation method of traditional Chinese medicine for treating hypertension |
CN107616261A (en) * | 2017-10-27 | 2018-01-23 | 羊楼洞茶业股份有限公司 | One kind thorn certain kind of berries green brick tea and preparation method thereof |
CN114224979A (en) * | 2021-12-23 | 2022-03-25 | 庞德东 | Medicine for softening blood vessel and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102078473A (en) | Traditional Chinese medicine preparation for treating chronic hepatitis b and preparation method thereof | |
CN101524469B (en) | A kind of traditional Chinese medicine compound preparation for treating congestive heart failure and preparation method thereof | |
CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
CN103961521A (en) | Traditional Chinese medicine composition for treating aplastic anemia and preparation method | |
CN101972353A (en) | Medicine composition for preventing and treating heart cerebrovascular diseases | |
CN103386022A (en) | Chinese medicine composition for treating tuberculous pleurisy | |
CN111643605A (en) | A Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, and its preparation method | |
CN104873705A (en) | Medicinal composition for treating angina pectoris of coronary heart disease and application thereof | |
CN105687788A (en) | Pharmaceutical composition capable of softening blood vessels and application thereof | |
CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
CN101524470A (en) | Traditional Chinese medicine preparation for curing angiocardiopathy stent restenosis and preparation method thereof | |
CN105267559B (en) | A kind of drug and preparation method thereof for treating diabete peripheral herve pathology | |
CN106109521A (en) | A kind of Radix Notoginseng oral liquid | |
CN104825905A (en) | Traditional Chinese medicine preparation for treating blood transfusion reaction and method for manufacturing traditional Chinese medicine preparation | |
CN104857121A (en) | Drug combination for curing hyperlipidemia and application thereof | |
CN103385931A (en) | Blood-sugar-lowering medicine composition | |
CN113332390A (en) | Traditional Chinese medicine composition for tonifying liver and kidney and preparation method thereof | |
CN105343688A (en) | Medicine composition for treating myocardial infarction and application thereof | |
CN100428944C (en) | Compound traditional Chinese medicine for improving eyesight and its prepn. method | |
CN111228382A (en) | Traditional Chinese medicine composition for preventing and treating diabetic complications and preparation method thereof | |
CN115869376B (en) | A compound traditional Chinese medicine composition for treating adult Still's disease | |
CN118767063B (en) | Traditional Chinese medicine composition for treating cardiovascular diseases, preparation method and application | |
CN102755580B (en) | Preparation method of chewable tablet of medicine for treating unstable angina pectoris | |
CN113499377B (en) | Composition with auxiliary blood fat reduction and chemical liver injury protection effects and preparation method and application thereof | |
CN117180387B (en) | Composition for treating wind-phlegm obstruction type peripheral facial paralysis and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160622 |
|
RJ01 | Rejection of invention patent application after publication |